Altogether, these studies provided robust functional genomic or pharmaceutical insights into RBM20 mutant and deficient DCM models, which can help to develop patient-specific therapeutic agents and strategies in the future. This evidence concerns the gene RBM20 and familial dilated cardiomyopathy.